$CYRX

STEFANOVICH ROBERT sold $2.8M of CYRX

STEFANOVICH ROBERT (Chief Financial Officer) sold 169,427 shares of Cryoport, Inc. (CYRX) at $16.27 ($2.76M total) on 2026-06-04.

Original reporting
SEC EDGAR · STEFANOVICH ROBERT
Published Jun 9, 2026, 1:11 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jun 9, 2026, 1:33 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$CYRX
Neutral
medium confidence
Mentioned
$CYRX
Relevance
6/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CYRXNeutralLow
01

Why it matters

The disclosure may influence short-term sentiment/positioning, but it does not include new guidance, trial results, contracts, or regulatory actions.

02

Market read

Traders may monitor CYRX for any follow-on insider activity or unusual volume, but the filing alone is not a fundamental catalyst.

03

What to watch

The article notes no pre-arranged 10b5-1 plan; traders may still treat the sale as discretionary, but the filing lacks context (e.g., tax liability, diversification needs).

Relevance 6/10Novelty 6/10Timing: after-hours/next-session read-through from the June 8 Form 4 filing

Background

The article reports an SEC Form 4 insider transaction for Cryoport, Inc. (CYRX) by its CFO.

Company-level read

Ticker impact

$CYRXNeutralMedium confidence
Context

Cryoport CFO Robert Stefanovich sold 169,427 shares in an open-market transaction worth about $2.76M, per SEC Form 4 filed June 8.

Expected impact

Low likelihood of a sustained price move; any reaction is likely limited to short-term sentiment/flow effects.

Evidence & confidence

The filing is a primary-source insider transaction, but it provides no new operational/regulatory/financial catalyst beyond the sale itself.

Market effects

Minimal; this is company-specific insider activity with no stated sector-wide catalyst.

None indicated.

None indicated.

Counterpoint

A single CFO open-market sale can be routine (tax/portfolio diversification) and may not reflect negative expectations.

Key entities

  • Cryoport, Inc.

    Subject of the SEC Form 4 insider sale by its CFO.

  • Robert Stefanovich

    Cryoport CFO who sold 169,427 shares in an open-market transaction.

Related articles

$CYRXMed

Cryoport, Inc. (CYRX): Results of Operations and Financial Condition

Cryoport, Inc. (CYRX) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 tm2622464d1_ex99-1.htm EXHIBIT 99.1 Exhibit 99.1 Cryoport Reports Second Quarter 2026 Financial Results · Second quarter revenue grew 8% year-over-year to $49.0 million · Life Sciences Services revenue increased 15% year-over-year · BioStorage/BioServices revenue grew 2